We advised The Rohatyn Group, a New York headquartered private equity and asset management house, and its portfolio company Optimapharm d.o.o (Croatia) in the acquisition of contract research group Crown CRO, which has a presence in the Nordics and Baltics.
The Rohatyn Group is a multi-strategy investment firm that is based in New York, NY. The firm offers multiple products across asset classes and investment approaches including hedge funds, credit, risk management, fixed income, macro and private market strategies. The firm has a presence in 15 cities globally.
Optimapharm is a leading European, mid-sized, full-service Clinical Research Organization (CRO) that provides successful tailor-made clinical research solutions to biotech, pharma and medical device companies.
Crown CRO, established in 2005, is a privately owned CRO with Finnish roots and a global network. Crown CRO specialises in customer-oriented, competitive and flexible services for clinical trials and regulatory affairs in Europe and the United States, serving the pharmaceutical, biotech, functional food, and medical device industries as well as contract research organisations. Headquartered in Finland, CrownCRO also has a strong presence in Sweden, Denmark, Norway, Estonia, Latvia and Lithuania.
